biostudies-literatureXie HClinical Comprehensive Drugs Evaluation in Jiangsu ProvinceSpecial Fund for Clinical Research of Nanjing Drum Tower HospitalNational Natural Science Foundation of China269-283https://www.ebi.ac.uk/biostudies/studies/S-EPMC10920562biostudies-literatureUnknown11(2)<h4>Introduction</h4>Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib efficacy in OA for personalized therapy optimization.<h4>Methods</h4>From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressedRheumatology and therapyPlasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis.PMC109205622021-LCYJ-PY-0772104105Zhu ZGe WXie HZhang YWei JAiniwaer GfalsePlasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis.<h4>Introduction</h4>Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib efficacy in OA for personalized therapy optimization.<h4>Methods</h4>From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed2024-01-01T00:00:00Z2024 Apr2026-07-14T20:53:54.406Z2026-06-24T03:04:12.718ZS-EPMC109205623823645610.1007/s40744-023-00636-z